SCHEMBL1668246

SCHEMBL1668246

CS(=O)(=O)N1CCC(c2cc(F)c(OC3CN(C(CO)c4ccc(C(F)(F)F)cc4)C3)c(F)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX2 P34913 1/20 0.38
CYP3A4 P08684 2/20 0.36
CYP3A5 P20815 2/20 0.36
RORC P51449 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
ENPP2 Q13822 2/20 0.35
NPY5R Q15761 1/20 0.35
IDO1 P14902 1/20 0.34
MMP2 P08253 2/20 0.34
MMP9 P14780 2/20 0.34
TRPV1 Q8NER1 1/20 0.34
MAPK1 P28482 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1668633 0.92 LMNA (0.38) LMNAKMT2AEPHX2CYP3A4CYP3A5
SCHEMBL2511739 0.88 LMNA (0.40) LMNAKMT2AEPHX2CYP3A4CYP3A5
SCHEMBL12198364 0.85 CCR3 (0.35)
SCHEMBL1668516 0.83 LMNA (0.38) LMNAKMT2AEPHX2CYP3A4CYP3A5
SCHEMBL1668410 0.81 KDM4E (0.49) LMNAKMT2AEPHX2CYP3A4RORC
SCHEMBL1668617 0.80 KDM4E (0.41) LMNAKMT2AEPHX2RORCKDM4E
SCHEMBL12198265 0.80 KDM4E (0.41) LMNAKMT2AEPHX2CYP3A4RORC
SCHEMBL1668765 0.79 KDM4E (0.40) LMNAKMT2AEPHX2RORCKDM4E
SCHEMBL12198357 0.78 CCR3 (0.35)
SCHEMBL1668262 0.78 KDM4E (0.48) LMNAKMT2ACYP3A4RORCKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 LMNA 3232/4885KMT2A 3355/4885EPHX2 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.